Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ACLX - Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

ACLX - Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Arcellx Inc.
  • ACLX is a clinical-stage biotech that aims to develop potentially "safer, more effective, and more broadly accessible" CAR-T cell therapies for cancers and incurable diseases.
  • On June 3, ACLX presented p1 data of their lead candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma (r/r MM) at the 2022 American Society of Clinical Oncology (ASCO) meeting.
  • The market reacted to the data enthusiastically and the stock of ACLX jumped >20% on June 6.
  • I take a close look and share my thoughts here.

For further details see:

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy
Stock Information
Company Name: Arcellx Inc.
Stock Symbol: ACLX
Market: NASDAQ
Website: arcellx.com
Menu
ACLX ACLX Quote ACLX Short ACLX News ACLX Articles ACLX Message Board
Get ACLX Alerts

News, Short Squeeze, Breakout and More Instantly...